Please ensure Javascript is enabled for purposes of website accessibility

Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?

By Keith Speights - May 15, 2021 at 7:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's still really early.

Ocugen (OCGN -4.30%) recently announced encouraging results from studies that indicated the potential for COVID-19 vaccine Covaxin to be effective against coronavirus variants. In this Motley Fool Live video, recorded on May 5, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Covaxin's success against emerging variants could help make Ocugen a big winner in the U.S. market.

Keith Speights: There's another story as well on the COVID-19 front. Ocugen, O-C-G-N is the ticker there. The company announced this week some studies that showed that the COVID-19 vaccine Covaxin appears to be effective against three of the new coronavirus variants. Ocugen stock soared on this news. How significant is this for the biotech?

Brian Orelli: Yeah. The studies are looking at serum from people that were vaccinated with Covaxin. They took the antibodies and looked at whether they could neutralize the different variants and that was able to neutralize the Brazil variant, the UK variant, and the India double mutant variant.

It's certainly good news and it will likely translate into protection of humans, but there's no way to know unless you run a prospective study and then look and see how many people that got placebo got infected with the different variants, and then how many people who got the vaccine were infected with the variants and show that there is a difference there. Beyond that, you can't really claim that it's protection. It's just a laboratory experiment that suggests that there should be protection.

Investors, I think, should be way more focused on Ocugen's plan to gain approval than actually worrying about the protection of the variants although obviously, it's good news. They licensed this drug from Bharat Biotech in India, but we still don't know whether the FDA will accept the study that was run by Bharat Biotech to gain emergency use authorization in the US, and that's the only place where Ocugen and it's still an open question. I think it's a much bigger issue for the evaluation of Ocugen and whether the vaccine can protect against the variants.

Speights: Yeah. You and I have spoken before about some of the challenges that Ocugen could have in getting that FDA authorization. Although over the longer term, a vaccine that can be effective against variants could have a shot anyway, no pun intended, could have a shot at being a success in the U.S. market.

Orelli: Yeah. I don't think the FDA is going to accept serum laboratory experiments as proof that the vaccine protects against the variants.

Speights: Right. The threshold is much higher and more definitive studies will definitely be needed.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.45 (-4.30%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.